|
WO2021008590A1
|
|
Isolated antigen-binding protein and application thereof
|
|
WO2020192648A1
|
|
Proteinaceous heterodimer and use thereof
|
|
CN112279915A
|
|
ICOS antibodies, genes, vectors, host cells and ICOS antagonists
|
|
CN112279914A
|
|
IL4RA antibodies, genes, vectors, host cells and IL4RA antagonists
|
|
CN112279916A
|
|
IL13RA1 antibodies, genes, vectors, host cells and IL13RA1 antagonists
|
|
WO2020077635A1
|
|
Anti-cd137 antibody and uses thereof
|
|
CN111094356A
|
|
Protein heterodimer and application thereof
|
|
EP3688023A1
|
|
Methods and compositions for cancer treatment
|
|
WO2019047885A1
|
|
Immunoconjugates comprising signal regulatory protein alpha
|
|
WO2018228442A1
|
|
Proteinaceous heterodimer and use thereof
|
|
EP3774898A1
|
|
Anti-cd27 antibodies and use thereof
|
|
WO2019178852A1
|
|
Ox40 polypeptide antigen and uses thereof
|
|
EP3363816A1
|
|
Anti-ox40 antibody and application thereof
|
|
US2018282422A1
|
|
Fully human antibody against human CD 137
|
|
CN105777906A
|
|
Anti-PD - L1 human antibody and application thereof
|
|
CN104403004A
|
|
Preparation and application of antibody-interferon heterodimer
|
|
CN104474548A
|
|
Product and method for preventing and/or treating chronic viral infection
|
|
CN103536917A
|
|
Use of interferon in treatment of tumor, and related product and method
|
|
WO2014107873A1
|
|
Agents for treating tumours, use and method thereof
|
|
WO2012155819A1
|
|
Hbv specific antibody
|
